TTR

Across TCGA pan-cancer cohorts, TTR mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TTR data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TTR mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TTR expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and HNSC are the cancer types where TTR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.850	0.537	.001	59	view →
UCEC	DFS	Tertile	III,IV	0.409	1.000	.020	12	view →
HNSC	OS	Tertile	II,III,IV	0.925	1.000	.014	6	view →
GBM	OS	Quartile	All	0.240	0.565	.028	5	view →
LUAD	OS	Median	III,IV	0.218	0.674	.007	4	view →
PDAC	DFS	Quartile	All	0.854	0.711	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TTR–CCRCC (DFS)

Open the CCRCC breakdown →